Results 121 to 130 of about 9,288 (216)

Toward Precision Electrochemical Sensing of CFTR Function in Cystic Fibrosis Models. [PDF]

Anal Chem
Miglione A, Blaconà G, Singh S, Cicero SL, Fuso A, Cimino G, Eramo A, Malapelle U, Lucarelli M, Cinti S.   +9 more
europepmc   +1 more source

Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy. [PDF]

J Cyst Fibros
Green N, Vu P, Xie J, Schwarzenberg SJ, Freedman S, Narkewicz M, Pittman J, Ratjen F, Rosenfeld M, Pope C, Duong J, Hoffman L, Heltshe S, Lusman SS, PROMISE Study Group.   +14 more
europepmc   +1 more source

Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor-Tezacaftor-Ivacaftor-A Pilot Study. [PDF]

Int J Mol Sci
Sankararaman S, Liu R, Sun X, Retuerto M, Schindler T, Roesch E, Sferra TJ, Drumm M, Ghannoum M, Zhang L.   +9 more
europepmc   +1 more source

Beyond CFTR: Ivacaftor's role in restoring cellular redox balance and preventing ferroptosis. [PDF]

Redox Biol
Rubin M, Artusi I, Rossetto M, Gucciardi A, Di Paolo ML, Bosello Travain V, Zeppilli D, Orian L, Miotto G, Friedmann Angeli JP, Cozza G.   +10 more
europepmc   +1 more source

Improved Quality of Life in Children With Cystic Fibrosis Who Received Transmembrane Conductance Regulator Modulators. [PDF]

Acta Paediatr
Svedberg M, Lundqvist F, Östrand HA, Krantz C, Ekman P, Imberg H.   +5 more
europepmc   +1 more source

Exposure to CFTR Modulators During Pregnancy in Cystic Fibrosis: Four Cases to Highlight Neonatal Diagnostic Challenges and Outcomes. [PDF]

Int J Neonatal Screen
Domenach L, Pagin A, Cisterne C, Audrezet MP, Couderc L, Monteil L, Roditis L, Murris M, Macey J, Fayon M, Bui S, Reboul MP.   +11 more
europepmc   +1 more source

Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry. [PDF]

ERJ Open Res
Dillenhöfer S, Schütz K, Burkhart M, Ellemunter H, Kappler M, Sieber S, Naehrlich L, Brinkmann F, Sutharsan S.   +8 more
europepmc   +1 more source

Functional, Cohort-Level Assessment of CFTR Modulator Responses Using Biobanked Nasal Epithelial Cells from Individuals with Cystic Fibrosis. [PDF]

J Pers Med
Aalbers BL, Amatngalim GD, Aarts EM, Rodenburg LW, den Hertog-Oosterhoff LA, Heijerman HGM, Beekman JM.   +6 more
europepmc   +1 more source

Therapeutic potential of synergistic mucociliary clearance for cystic fibrosis airways by β-adrenergic plus cholinergic agonists. [PDF]

J Clin Invest
Joo NS, Birket SE, Keith JD, Ianowski JP, Luan X, Spano J, Bollyky JB, Dobry MN, Sabater JR, Williams RW, Engelhardt JF, Wine JJ, Milla CE.   +12 more
europepmc   +1 more source

The European Medicines Agency's review of elexacaftor/tezacaftor/ivacaftor: extending its use to all people with cystic fibrosis aged 2 years and older who do not have two class I <i>CFTR</i> variants. [PDF]

Eur Respir J
Drai C, van der Woude HJ, Lexmond AJ, van den Hoorn T, Mol PGM, Leacy FP, Przybyszewska A, Sepodes B, Castelnovo T.   +8 more
europepmc   +1 more source